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Abstract Non-hereditary angioedema (AE) with normal C1
esterase inhibitor (C1INH) can be presumably bradykinin- or
mast cell-mediated, or of unknown cause. In this systematic
review, we searched PubMed, EMBASE, and Scopus to pro-
vide an overview of the efficacy of different treatment options
for the abovementioned subtypes of refractory non-hereditary
AE with or without wheals and with normal C1INH. After
study selection and risk of bias assessment, 61 articles were
included for data extraction and analysis. Therapies were de-
scribed for angiotensin-converting enzyme inhibitor-induced
AE (ACEi-AE), for idiopathic AE, and for AE with wheals.
Described treatments consisted of ecallantide, icatibant,
C1INH, fresh frozen plasma (FFP), tranexamic acid (TA),
and omalizumab. Additionally, individual studies for anti-
vitamin K, progestin, and methotrexate were found. Safety
information was available in 26 articles. Most therapies were
used off-label and in few patients. There is a need for addi-
tional studies with a high level of evidence. In conclusion, in
acute attacks of ACEi-AE and idiopathic AE, treatment
with icatibant, C1INH, TA, and FFP often leads to symp-
tom relief within 2 h, with limited side effects. For prophy-
lactic treatment of idiopathic AE and AE with wheals,
omalizumab, TA, and C1INH were effective and safe in
the majority of patients.
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C1INH C1 esterase inhibitor
CSU Chronic spontaneous urticaria
FFP Fresh frozen plasma
fXII Coagulation factor 12
HAE Hereditary angioedema
RoB Risk of bias
MTX Methotrexate
QoL Quality of life
RCT Randomized controlled trial
SAE Serious adverse event
TA Tranexamic acid
TEAE Treatment-emergent adverse event
Introduction
Angioedema (AE) frequently occurs as part of urticaria, a
disease characterized by the development of wheals, AE, or
both [1, 2]. AE with wheals, also known as chronic spontane-
ous urticaria (CSU), is presumably mast cell-mediated [1–3].
AE without significant wheals can be the presenting symptom
of a variety of diagnoses, such as hereditary AE caused by C1
esterase inhibitor (C1INH) deficiency, resulting in the release
of the key mediator bradykinin [2]. Accumulation of
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bradykinin can also be caused by the use of angiotensin-
converting enzyme inhibitors (ACEi-AE) in patients with nor-
mal C1INH [2, 4]. ACEi-AE is estimated to occur in up to
0.68 % of patients who receive ACE inhibitors [5]. However,
a majority of patients suffer idiopathic acquired AE, which
implies AE with normal C1INH with no family history of
AE, in which known causes of AE have been excluded [2,
3]. It is unclear to what extent idiopathic AE is similar to
angioedema with wheals (CSU) [3], or to presumably
bradykinin-mediated subtypes of AE.
Second-generation antihistamines are used as prophylactic
treatment of AE with wheals and idiopathic AE [1, 2].
Antihistamines and corticosteroids, and, in life-threatening
cases, adrenaline, represent the standard emergency room
treatment of acute attacks of AE [2, 4, 6, 7]. CSU is thought
to affect 0.5–1 % of the global population at any given time,
with an estimated 67 % of patients with CSU shown to have
both hives and AE and 1–13% to have AE alone [8, 9]. In AE
with wheals, daily treatment with antihistamines does not al-
ways lead to a complete absence of symptoms [1], and it is
estimated that every third or fourth patient remains symptom-
atic even despite high-dose antihistamine treatment [8, 9].
Omalizumab is effective in patients with CSU [1, 10–15],
although it has not been studied extensively in AE without
wheals. Patients with ACEi-AE generally do not respond to
conventional therapy [5, 6]. Pathophysiology suggests that
drugs registered for hereditary angioedema (HAE) due to
C1INH deficiency could also be effective in ACEi-AE. Several
drugs are currently available, including (1) antifibrinolytic agents
such as tranexamic acid (TA); (2) attenuated androgens such as
danazol; (3) replacement of deficient proteins using fresh frozen
plasma (FFP); (4) C1INH concentrates, which inhibit the forma-
tion of bradykinin; (5) the selective plasma kallikrein inhibitor
ecallantide; and (6) the selective bradykinin B2 receptor antago-
nist icatibant [2]. Some of these drugs are licensed to treat acute
attacks, whereas others are used for prophylactic treatment [2].
The efficacy of these drugs in refractoryAEwith normal C1INH
has not been fully elucidated.
This systematic literature review aims to provide an over-
view of therapeutic options and their efficacy in patients with
AEwith normal C1INH, but refractory to conventional therapy.
We have distinguished between treatment of acute attacks vs.
prophylactic treatment and included bradykinin-mediated and
mast cell-mediated non-hereditary AE as well as idiopathic AE.
Methods
This systematic literature review was conducted using
the criteria mentioned in the Preferred Reporting Items




CBO guidelines, Trip Database, and the Cochrane Library
were searched for guidelines up to 20th April 2015 using sev-
eral synonyms for the domain, angioedema, and determinant,
treatment options (Table 1). Subsequently, primary evidence
electronic databases PubMed, EMBASE, and Scopus were
searched for articles up to 20th April 2015 using the domain
and determinants as previously described. Synonyms for out-
come measurements were not included in the search strategy
so as to maximize the yield of articles and to allow for different
outcome measures, including but not limited to time to initial
or complete response and decrease in attack frequency or se-
verity. The search was limited by title or abstract and, in
Scopus, by title, abstract, or keywords.
Inclusion and Exclusion Criteria
Articles were included when the described study populations
suffered ACEi-AE, AE with wheals (CSU), or idiopathic AE
with normal C1INH. Furthermore, only articles describing
pharmacological treatment of AE were included. This includ-
ed both observational studies (case report and case series) and
intervention trials (cohort studies or randomized controlled
trials, RCTs). Any pharmacological treatment other than anti-
histamines up to fourfold, prednisolone, or adrenaline could
be included. Articles were considered appropriate to be in-
cluded only when sufficient details regarding type of treat-
ment, dose, interval between doses, time to initial response,
and time to maximum or complete response were described.
Articles describing only ineffective therapies were described
separately. For full understanding of scientific content by the
authors who performed the selection of studies, only articles
written in English, Dutch, or German were included. Recent
Table 1 Search syntax performed on 20th April 2015 in PubMed,
EMBASE, and Scopus
Search
(Angioedema OR ‘angio edema’ OR angioedemas) AND (treatment OR
therapy OR antihistamines OR (ciclosporine OR CsA OR
cyclosporine) OR (omalizumab OR (anti IgE)) OR (danazol OR
‘attenuated androgen’ OR androgen) OR C1 inhibitor concentrate OR
(tranexamic acid OR TTA OR cyklokapron OR AMCA OR ‘trans
aminomethyl cyclohexane carboxylic acid’) OR biological OR
antileukotrienes OR (‘H2 antagonist’ OR ‘histamine antagonist’) OR
(TCA OR antidepressant) OR (icatibant OR ‘bradykinin receptor
antagonist’) OR (MTX OR methotrexate) OR (AZA OR azathioprine
OR Imuran) OR (corticosteroids OR prednisone OR
glucocorticosteroids) OR Adrenaline OR sulphasalazine OR (dapson
OR dapsone) OR hydroxychloroquine OR Plasmapheresis OR
(‘intravenous immunoglobulin’ OR IVIG)) OR (‘Fresh Frozen
Plasma’ OR FFP))
Search term ‘biological’ was entered as ‘biologicals’ in EMBASE
database.
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articles for which only the title and abstract were available,
such as congress abstracts, were included only if sufficient
information about the patient(s), treatment regimen, and re-
sponse were described. For icatibant only, when dose was
missing, it was assumed that 30 mg was used due to the pack-
aging of this product. Therefore, these articles could be includ-
ed, although the dose was shown as Bnot reported^ in the
results. Articles regarding AE with wheals could only be in-
cluded when treatment results specifically for AE symptoms
could be extracted rather than only for the symptoms wheals
and itch. Outcome measurements could differ for articles re-
garding an acute attack or prophylactic treatment: in acute
settings, initial and complete responses refer to the resolution
of a single attack of swelling, whereas in prophylactic or
chronic settings this refers to a decrease in attack frequency
or severity.
Studies were excluded when AE was caused by hereditary
or acquired complement C1 inhibitor (C1-INH) deficiency,
coagulation factor 12 (fXII) mutation, formerly known as
HAE type 3, or other known causes of AE, including allergy,
or when AE was an adverse effect of any therapy other than
ACEi.
Selection of Studies
Unique titles and abstracts and subsequently full texts were
screened for eligibility. Articles published in or after 2013
were screened by at least two independent reviewers (ME,
MG, and MB), results were compared, and disagreements
were discussed and resolved. Articles published before 2013
were screened by one reviewer (ME), and for assessment of
unclear articles only, a second reviewer (MB) was available.
Risk of Bias
Risk of bias (RoB) for each study was assessed by one review-
er (MG) and verified by a second reviewer (ME). To allow for
a careful assessment of observational studies as well as
intervention studies, criteria for risk of bias assessment from
the Cochrane Handbook for Systematic Reviews of
Interventions [17] were supplemented with items from the
CARE guidelines checklist [18]. The risk of selection bias,
performance bias, detection bias, attrition bias, and selective
reporting bias was assessed. A low risk of bias was preferred
and therefore displayed as a positive finding (+), whereas a
high risk of bias was undesirable and displayed as a negative
finding (−). The risk of selection bias was considered low (+)
for observational studies when symptoms and important clin-
ical findings were described. The risk of performance bias was
considered low (+) when the chosen treatment option and dose
regimen were both recorded. The risk of detection bias was
assessed with regard to (1) effect of treatment and (2) adverse
events and was considered low if this was noted in the article.
In case of multiple patient groups including more than one
type of AE, the risk of detection bias was considered low only
when results could be extracted for the subgroups separately
and unclear (+/−) when results were described for the total
group. The risk of attrition bias was low (+) when reasons
for exclusion or dropout were reported, and for controlled
studies, the dropouts were balanced between treatment and
placebo groups. The risk for reporting bias was low (+) when
all prespecified outcomes were fully addressed in the results.
Authors of RCTs were contacted to retrieve missing trial de-
tails. All evaluations were compared and disagreements be-
tween authors were discussed and resolved.
Data Extraction and Synthesis
For each study, data extraction was performed by one review-
er and verified by a second reviewer (ME and MG). Data
regarding the study design, therapy, previous therapies, and
effect of the described therapy were recorded in tables. For
treatment of acute attacks and prophylactic treatment of AE,
available efficacy results were described per subtype and per
treatment option. Definitions for response were adopted from
the original articles. Articles describing ineffective treatment
options were described separately. If information about ad-
verse effects was available, this was collected additionally
for each type of treatment. A distinction between serious ad-
verse effects (SAEs) and less severe treatment-emergent ad-
verse events (TEAEs) was made. Additionally, only adverse
events possibly, probably, or definitely related to treatment
were reported. Adverse effects reported by placebo-treated
patients were not taken into account. Due to the high amount
of available case reports and low amount of controlled studies,
and since outcomemeasures varied among the study studies, a
meta-analysis could not be performed. Instead, results are de-
scribed using narrative summary technique.
Results
Search Results and Quality Assessment
The search in secondary evidence databases yielded no avail-
able aggregated evidence. The search in PubMed, EMBASE,
and Scopus yielded 5107 original articles (Fig. 1). After
screening titles and abstracts, 4952 articles were excluded.
Subsequently, 155 full texts were screened for eligibility, lead-
ing to the exclusion of 94 further articles, including 53 articles
with a lack of usable information, the use of conservative treat-
ment in 40 articles, and overlap in study population in one
article. The remaining 61 articles included 53 full articles and
eight (congress) abstracts. Of the 61 included articles, 38 de-
scribed treatment of AE in acute settings, including 3 RCTs, 2
cohort studies, 4 case series, and 29 case reports. Additionally,
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26 of the 61 articles described prophylactic settings, including 1
RCT, 5 cohort studies, 9 case series, and 11 case reports. Three
articles described both acute and prophylactic treatment.
All 61 articles underwent RoB assessment (Tables 2 and 3).
All of the four included RCTs had a low risk of bias. Of the 57
descriptive studies, 46 had a low risk of bias and 11 had an
unclear risk of at least one type of bias. Only 26 addressed
safety results with regard to efficacy outcomes.
Treatment of Acute Attacks of AE
With regard to acute attacks of AE refractory to conventional
treatment including antihistamines, corticosteroids, and adren-
aline, the included articles described treatment of two
subtypes: ACEi-AE and idiopathic AE.
ACEi-AEwas addressed in 24 articles describing treatment
of acute attacks in 154 patients, with study sizes varying from
1 to 58 patients. Outcome measures were (1) time to response
(Fig. 2a and Table 4) and/or (2) proportion of patients with
response (Fig. 2b and Table 4). As shown in Fig. 2a, described
treatment strategies consisted of icatibant (42 patients in ten
articles including one RCT) [5, 6, 21, 24, 26, 27, 31, 33, 36,
37], C1INH (14 patients in five articles) [22, 25, 28, 38, 39],
FFP (13 patients in six articles) [23, 29, 30, 32, 35, 40], and
kanokad (concentrate of vitamin K-dependent coagulation
factor anti-vitamin K antagonist in one patient using anti-
vitamin K medication concomitantly) [34]. In the 21 included
studies for icatibant, C1INH, and FFP, the (median) time to
initial response ranged from a fewminutes up to 150min, with
one outlier up to 48 h [38]. Time to complete response ranged
from 0.5 to 48 h. As shown in Fig. 2b, ecallantide was
Fig. 1 Flowchart of the included
and excluded articles















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Clinic Rev Allerg Immunol
described additionally in 84 patients in two RCTs [4, 7].
Results for ecallantide were not significant: one RCT identi-
fied a difference in response rate vs. placebo of 16 % (95 %
confidence interval, −11 to 41 %) [4], and a second RCT
revealed a difference in response rate vs. placebo of 10 %
(95 % confidence interval, −14 to 34 %) [7]. The level of
evidence for C1INH, FFP, and icatibant was low, compared
to ecallantide, due to lack of controlled studies. In conclusion,
in treatment of acute attacks of ACEi-AE, no significant dif-
ferences in the response rate between ecallantide and placebo
were shown, and icatibant, C1INH, and FFP had similar times
to response, mostly less than 2 h.
Idiopathic AEwas addressed in 12 articles describing treat-
ment of acute attacks in 84 patients. Effect of treatment was
described as time to response (Fig. 2c and Table 5) or propor-
tion of patients with response (Table 5). Treatment strategies
consisted of icatibant (56 patients in nine studies) [19, 20, 41,
44, 46–50], TA (24 patients in one study) [19], C1INH (three
patients in three articles) [19, 43, 45], and ecallantide (one
patient) [42]. As shown in Fig. 2c, the time to initial response
for C1INH ranged from 20 to 120 min and for icatibant from
20 to 45 min, and (median) time to complete response for
ecallantide was 1 h. For C1INH, (median) time to complete
response was also 1 h, and for icatibant this ranged from
45 min up to 26 h. In addition to Fig. 2c, one study reported
response to TA in 13 of 24 patients (54 %) [19]. In conclusion,
in acute attacks of idiopathic AE, C1INH, icatibant, and
ecallantide had times to response often within 2 h, and TA
was effective in more than 50 % of patients.
Prophylactic Treatment of AE
With regard to recurrent AE refractory to conventional treat-
ment, included articles about prophylactic treatment described
two subtypes: AE with wheals and idiopathic AE.
AEwith wheals was addressed in 11 articles describing 230
patients. Effect was shown as time to response (Fig. 2d and
Table 6) [53, 54, 62–64, 66–71]. All articles described treat-
ment with omalizumab after unsuccessful treatment with an-
tihistamines and often additional ineffective treatment options.
One manuscript detailed two RCTs for which the results re-
garding urticaria had been published previously [10, 14].
However, in the included manuscript, specific results with
regard to AE were described [53]. In the other articles, which
consisted of cohort studies and case series or case reports, the
time to initial effect ranged from 1 day to 60 days after admin-
istration, and 10 of 22 patients achieved complete remission
within a time range varying from 1 day to <150 days [54,
62–64, 66–71]. In conclusion, in prophylactic treatment of
AE with wheals, omalizumab had a broad range of time to
response and was effective in almost half of the patients.
Lastly, prophylactic treatment of idiopathic AE was ad-
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54–61, 64, 65, 72–74]. Efficacy was shown as proportion of
patients with response (Fig. 2e and Table 7) or time to re-
sponse (Fig. 2f and Table 7). As shown in Fig. 2e, described
treatment options were TA (126 patients in six studies) [19,
48, 55, 56, 58, 59], progestin (20 patients in one study) [57],
and C1INH (two patients in two studies) [43, 74]. When com-
bining studies, TA led to improvement of symptoms in 92
patients (73 %) and a complete absence of symptoms in an-
other 20 patients (16 %; Table 7). Progestin provided im-
provement in 19 of 20 patients and C1INH in two of two
patients. Figure 2f shows the results for omalizumab (19 pa-
tients in six articles) [54, 60, 61, 64, 72, 73] and methotrexate
(MTX, one patient) [65]. For omalizumab, in 12 patients
(63 %), no further attacks occurred after starting treatment,
and the time to initial response ranged from 1 day to 120 days.
MTX provided improvement in one patient after 28 days of
treatment. In conclusion, in prophylactic treatment of idio-
pathic AE, TA, omalizumab, and C1INH, as well as progestin
and MTX, were effective in a majority of patients.
Ineffective Treatment Options
Ineffective treatment options were described in 21 patients in
12 articles (Table 8) [25, 31, 37, 38, 43, 48, 49, 51, 52, 60, 62,
75]. Nine of them overlap with the previously described arti-
cles since they had additionally described a successful treat-
ment option for at least one of the subtypes of AE [25, 31, 37,
38, 43, 48, 49, 60, 62]. In three articles, only ineffective treat-
ment options were described [51, 52, 75]. In total, ineffective-
ness was recorded for TA (12 patients), C1INH and FFP (five
patients each), and icatibant, MTX, and omalizumab (two
patients each). In four patients, more than one therapy was
recorded ineffective, in addition to conservative treatment
with antihistamines, corticosteroids, and/or adrenaline. In con-
clusion, ineffectiveness was reported for several therapeutic
options commonly used in bradykinin-mediated and mast
cell-mediated AE and was reported for individual cases only,
resulting in low numbers for each drug.
Safety
The presence or absence of adverse effects was addressed in
25 of the 61 included articles [4–7, 19, 21, 22, 27, 42, 46,
54–60, 62–66, 70, 72, 73] (Table 9). The other 36 articles
did not report information on this topic. Thus, safety informa-
tion was available for 315 patients treated with either
ecallantide (87 patients), icatibant (37 patients), TA (125 pa-
tients), omalizumab (34 patients), progestin (20 patients),
C1INH (ten patients), or MTX (two patients).
A distinction between SAEs and less severe TEAEs was
adopted from the included articles, if available. Additionally,
only adverse events possibly, probably, or definitely related to
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patients, including five AE episodes during treatment with
ecallantide (6 % of those treated with ecallantide) and one
myocardial infarction during treatment with TA (0.8 %).
TEAEs were reported in 13 patients treated with ecallantide
(15 %) and 12 treated with icatibant (32 %; all local and
related to the administration method). At least 19 patients
treated with TA (15 %) reported TEAE, and at least nine
treated with omalizumab (26 %). However, TEAEs were pre-
sented in the total study populations including also HAE and
CSU patients; therefore, the number of patients experiencing
adverse effects may be higher. For progestin and MTX,
TEAEs were addressed in one article each, where TEAEs
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Fig. 2 a–d Responses to treatment. NA not available, Anti-vit K anti-
vitamin K, C1INH complement 1 esterase inhibitor, MTX methotrexate,
TA tranexamic acid, P progestin. Numbers on the Y-axis represent the
reference number for each study; n indicates the number of patients
included from each study. Not shown in (c): Mansi et al., 13 of 24 patients
had partial response to tranexamic acid. Not shown in (d): Zazzali et al.,
in 208 patients treated with omalizumab, the mean proportion of AE-free
days was 90.1–95.8 % vs. 88.7 % for placebo
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were also presented in the total study population including
also HAE and CSU patients. For C1INH, no TEAE was re-
ported. In addition, one article described the use of
omalizumab during two pregnancies, with no developmental
abnormalities in both children [66]. In conclusion, SAEs were
reported in 2 % and TEAE in 17 % of patients.
Discussion
In this systematic review, we found several treatment options
for patients with refractory AE. For acute attacks of AE, sev-
eral articles described treatment with icatibant, C1INH, TA,
FFP, and ecallantide. For prophylactic treatment of AE,
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omalizumab, TA, and C1INHwere shown effective, and, with
fewer included articles, also progestin and MTX. The de-
scribed treatments showed good efficacy in addition to a fa-
vorable safety profile with a low number of mostly mild and
self-limiting adverse effects. A limitation of the available lit-
erature was the low level of evidence for all treatment options,
except ecallantide and icatibant.
In ACEi-AE, high-quality studies were performed for
ecallantide, but the response rates compared to placebo were
not significant. Many patients responded quickly after treat-
ment with icatibant, C1INH, and TA, but most of the included
studies were not controlled and therefore of lower quality in
terms of scientific reliability. FFP has shown similar results,
but since FFP also contains other substrates including
prekallikrein and high-molecular-weight kininogen, it has
been hypothesized to have the potential to worsen an acute
attack of AE since new bradykinin can be formed [76].
Treatment of refractory ACEi-AE mostly consisted of drugs
known for treatment of HAE. The rationale for this is that
ACEi-AE is presumably bradykinin-mediated [2]. Icatibant
had a similar time to response in ACEi-AE, as previously
shown in HAE patients [77]. Ecallantide had stronger benefi-
cial results in HAE patients [78] compared to ACEi-AE pa-
tients, partially due to a high response rate in the placebo
group. Additional RCTs in HAE patients revealed time to
onset of relief within 2 h for pasteurized C1INH, nanofiltered
C1INH, and recombinant human C1INH (rhC1INH) [79–81].
In many of the cases included in this review, the onset of relief
after C1INH was reported within 1 h of administration, and
efficacy results may therefore be quite consistent with the
results of C1INH treatment in acute HAE attacks. Very recent-
ly, the Canadian Agency for Drugs and Technologies in
Health performed a non-systematic literature search and pro-
vided a summary of four available guidelines for urticaria and
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AE, which supports that icatibant, C1INH, ecallantide, and
FFP may be useful in the treatment of ACEi-AE [82]. In
addition to the results of these therapies in ACEi-AE, we show
in the current review that these therapies, with icatibant as the
most often studied, may also be effective in the treatment of
acute attacks of idiopathic AE. In conclusion, in patients suf-
fering ACEi-AE or an acute attack of idiopathic AE,
ecallantide seems to have an effect in a limited number of
patients, if any, whereas icatibant, C1INH, TA, and FFP often
lead to symptom relief within 2 h, in addition to a good safety
profile.
For AE with wheals, also known as CSU, omalizumab was
the only treatment option described when conservative treat-
ment had failed. A high success rate, good safety profile, and
rapid responses were described, as was shown extensively in
patients suffering CSU, which by definition includes AE with
wheals [1, 10–15]. In patients suffering idiopathic AE, we
show that both licensed HAE drugs and omalizumab seem
to have a beneficial effect in a substantial amount of patients,
even in those who are very refractory and have had many
other treatments prior to the described treatment. When com-
paring with ACEi-AE, it appears that idiopathic AE responds
even more rapidly upon treatment with icatibant, C1INH, or
ecallantide. This suggests a role for both bradykinin and mast
cells (histamine) in idiopathic AE with normal C1INH, al-
though this was not the objective of the current review.
Additionally, in one patient treated with C1INH and two treat-
ed with FFP, the time to response of an acute attack was
Table 4 Results of acute setting studies: subtype ACEi-induced angioedema
Author Year Study
design
Size Previous therapy Therapy Dosage Effect
Lewis [4] 2015 RCT 58 + 18 AH +C + E +H2 Ecallantide 10–60 mg Predefined criteria ≤6 h met in 88 vs. 72 % for
PLC (difference = 16 %; 95%CI = 11–41)
Bernstein [7] 2015 RCT 26 + 24 AH +C + E Ecallantide 30 mg Discharge criteria ≤4 h in 31 vs. 21 % for PLC
(difference = 10 %; 95 %CI = 14–34 %)
Bas [5] 2015 RCT 13 + 14 None Icatibant 30 mg Median IR = 120 min (95%CI = 60–480) vs. 702 min
(480–1080); CR = 8.0 vs. 27.1 h (3.0–16.0)
Bova [21] 2015 CS 13 AH +C + E Icatibant 30 mg IR = 30 min (IQR = 27.5–70); CR = 5 h (IQR = 4–7)
Bas [6] 2010 CS 8 None Icatibant 30 mg IR = 50.6 min (SD = 21); CR = 4.4 h (SD = 0.8)
Volans [31] 2013 CS 2 AH +C + E + TA Icatibant 30 mg IR = 20 min; CR = 4 h
Bartal [24] 2015 CR 1 AH+C + E +H2 Icatibant 30 mg IR within minutes; CR = 0.5 h
Charmillon [26] 2014 CR 1 n.r. Icatibant 30 mg CR = 1 h
Crooks [27] 2014 CR 1 AH+C + E Icatibant 30 mg IR = 30 min; CR = 24 h
Gallitelli [33] 2012 CR 1 None Icatibant 30 mg CR = 10 h
Bas [36] 2011 CR 1 C Icatibant 30 mg IR = 55 min; CR = 4 h
Schmidt [37] 2010 CR 1 AH+C + E +C1INH Icatibant 30 mg IR = 15 min
Greve [22] 2014 CS 10 None C1INH (B) 1000 U IR = 88 min (SD = 38); CR = 10.1 h (SD = 3)
Lipski [25] 2015 CR 1 C + E + FFP C1INH (B) 20 U/kg CR < 1 h
Rasmussen [28] 2014 CR 1 None C1INH 15 U/kg IR = 40 min; CR < 24 h
Dehne [38] 2007 CR 1 AH+C + E + P + FFP C1INH (B) 1000 IE IR = 2 days after initial worsening in the first 24 h
Nielsen [39] 2006 CR 1 AH+C C1INH (B) 1500 U IR = 20 min
Hassen [23] 2013 CS 7 AH +C + E +H2 FFP 1-3 U IR = 2 h; CR = 48 h
Stewart [35] 2012 CR 2 C FFP 2 U IR = 2.5 h in 1 patient; CR = 4.75 in the other
Yates [29] 2014 CR 1 None FFP 2 U CR= 4 h
Bledsoe [30] 2013 CR 1 AH+C + E +H2 FFP 2 U IR within a few hours. CR < 48 h
Bolton [32] 2012 CR 1 Not known FFP 2 U CR= 2 h
Karim [40] 2002 CR 1 AH+C FFP 4 U IR < 2 h
Millot [34] 2012 CR 1 AH+C + E Kanokad 1500 U IR = 20 min; CR = 8 h
ForSize, only the number of patients included for describing therapies are presented in the table. In controlled studies, the number of patients treated with
study medication vs. those treated with placebo or comparative treatment are presented as x + y. The effect of treatment is presented as initial response
(IR) and complete response (CR)
CS case series, CR case report, ACEi angiotensin-converting enzyme inhibitor, n.r. not reported, AH antihistamine, C corticosteroids, E epinephrine,
C1INH C1 inhibitor concentrate (B: Berinert P), TA tranexamic acid, H2 H2 antagonist, FFP fresh frozen plasma, P pantoprazole, PLC placebo
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Table 5 Results of acute setting studies: subtype idiopathic angioedema
Author Year Study design Size Previous therapy Therapy Dosage Effect
Bouillet [20] 2014 Cohort 48 Unknown Icatibant n.r. Median time to CR= 26.6 h
(IQR = 8.3–46)
Bertazzoni [41] 2015 CR 1 AH+C + E Icatibant 30 mg IR = 20 min
Seoane [50] 2014 CR 1 AH+C Icatibant n.r. BRapid response^
Vela Vizcaino [48] 2014 CR 1 AH+C + E Icatibant n.r. CR = 45 min
Montinaro [44] 2013 CR 1 AH+C Icatibant 30 mg IR = 45 min; CR = 9 h
Colás [49] 2012 CR 1 AH+C + E +H2 +C1INH Icatibant 30 mg IR = 25 min
Lleonart [46] 2012 CR 1 AH+C + E Icatibant 30 mg IR = 30 min; CR = 6 h
Sridhara [47] 2012 CR 1 AH+C + E +H2 +H + LTRA Icatibant 30 mg IR = 20 min
Mansi [19] 2014 Cohort 1 None Icatibant 30 mg CR= 4 h
2014 Cohort 24 None TA ≤6 g/day Decreased severity and duration
of symptoms in 13 (54 %)
2014 Cohort 1 None C1INH 1000 U CR= 1 h
Stahl [43] 2014 CR 1 AH+C + E +H2 + TA +H +
AB + LTRA+ FFP + Icatibant
C1INH 20 U/kg IR = 2 h
O’Keefe [45] 2013 CR 1 C + E C1INH 500 U IR = 20 min
Nanda [42] 2014 CR 1 AH+C + E Ecallantide 30 mg CR< 1 h
The effect of treatment is presented as initial response (IR) and complete response (CR)
CS case series,CR case report, n.r. not reported,AH antihistamine,C corticosteroids,E epinephrine,C1INHC1 inhibitor concentrate, TA tranexamic acid,
H2 H2 antagonist, FFP fresh frozen plasma, LTRA leukotriene receptor antagonist, H hormones, AB antibiotics, H hydroxychloroquine










Zazzali [53] 2014 RCT 208 n.r. AH OMA 75–300/4 Mean proportion AE-
free days = 90.1–
95.8 % vs. 88.7 %
3




vd Elzen [62] 2014 CS 3 2,4,9 AH +C + LTRA+H2 +AB+
I +MTX+HC
OMA 150–300/2–4 CR < 9 days 24
Groffik [63] 2010 CS-1 1 1 AH +C + LTRA OMA 300/2 IR < 2 months 4
CS-2 1 19 AH +C + LTRA OMA 150/2 CR < 2 months 4
Büyüköztürk [64] 2012 CS 1 7 AH OMA 225/4 IR <1 week 8
Ghazanfar [66] 2015 CR 1 n.r. AH +C + I OMA 150/2→ 300/4 CR < 1 day 48
Wieder [67] 2015 CR 1 n.r. AH +C + LTRA+ I + O OMA 300/4 IR after first dose 29
Kutlu [68] 2014 CR 1 n.r. AH +C + E OMA 300/4 IR = 2 months;
CR = 3 months
3
Ozturk [69] 2014 CR 1 n.r. AH +C +O OMA 300/4 No further attacks 3
Sánchez-Machín [70] 2011 CR 1 9 AH +C + I + O OMA 300/2→ 300/6 IR = <3 days;
CR = 14 days
36
Korkmaz [71] 2010 CR 1 n.r. AH +C + LTRA+H2 +AB+
I
OMA 300/2 IR = 2 days;
CR = 14 days
n.r.
Dosage scheme presented as milligrams administered every x weeks. An arrow indicates a dose adjustment during the treatment period. The effect of
treatment is presented as initial response (IR) and complete response (CR)
CS case series,CR case report, n.r. not reported,AH antihistamine,C corticosteroids, E epinephrine,C1-inhC1 inhibitor concentrate, TA tranexamic acid,
H2 H2 antagonist, LTRA leukotriene receptor antagonist, AB antibiotics, I other immunosuppressant, MTX methotrexate, HC hydroxychloroquine, O
other therapy
a Results mentioned for the whole study population, which may be larger than the patients included in this review
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reported to be 2 days [38]. In such cases, one should be aware
of the natural course of an attack [1–3, 83]. Furthermore, also
for this subtype, the level of evidence is low, and controlled
studies remain to be performed. In conclusion, omalizumab,
TA, and C1INH were effective and safe in a majority of pa-
tients in need of prophylactic treatment of refractory idiopath-
ic AE or AE with wheals.
One needs to keep in mind that all treatment options de-
scribed are currently off-label in these patient groups world-
wide, except for omalizumab in AE with wheals (CSU), and
that the findings should be confirmed in clinical trials. Due to
the fact that most therapies described have only been regis-
tered for other indications recently, the efficacy and safety for
the current subtypes of non-HAE have not been studied yet. It
remains unclear which (groups of) patients derive a beneficial
effect from each type of treatment. For C1INH, a beneficial
effect was described even in patients who failed to respond to
icatibant and/or FFP. On the contrary, in ACEi-AE and idio-
pathic AE, patients failed to respond to C1INH, but did re-
spond to icatibant or TA. Similar results were seen for TA,















Reduction recurrences in 43 (98 %) n.r.
Wintenberger
[55]
2014 Cohort 25 n.r. n.r. TA 2–2.5 g/
day
Attack frequency from 15.2
(range = 2–50) to 3.7 (0–18) per
6 months. No response in 6 (24 %)
6
Firinu [56] 2015 Cohort 16 n.r. AH +C TA 1.5–3 g/
day
50 % attack frequency decrease in 8





2010 CS 25 n.r. AH +C TA 3 g/day CR in 12 (48 %), PR in 11 (44 %), no
response in 2 (8 %)
20
Cicardi [59] 1999 CS 15 Median 6 AH TA 3 g/day No further attacks in 8 (53 %), 7





2014 CR 1 3 AH+C + E + C1INH TA 3 g/day Attack frequency decrease from
weekly to 3/8 weeks
n.r.
Saule [57] 2012 Cohort 20 n.r. AH Progestin n.r. Improvement in 19 (95 %) 32,4
Rijo Calderón
[54]
2013 Cohort 4 n.r. AH + C + dapsone OMA 150–300/
2–4
IR < 1 month n.r.
Azofra [60] 2015 CS 8 n.r. (AH +C +) TA OMA 300/4 IR = 2–14 days 6–12 m
Sands [61] 2007 CS-1 1 6 AH+C + E +H2 OMA 300/3 No further attacks 24
CS-2 1 4 AH+C +H2 OMA 375/2 No further attacks 7
CS-3 1 9 AH+C + LTRA+H2 OMA 300/4 1 minor attack in 2 years >12
Büyüköztürk
[64]
2012 CS-1 1 10 AH+C +H+ O OMA 300/4 CR within 4 months n.r.
CS-2 1 15 AH+C +H + IVIG + I OMA 300/4 No further attacks n.r.
von Websky
[72]
2013 CR 1 n.r. AH +C + LTRA+AB OMA 300/4 CR= 2 days 18
Suna [73] 2009 CR 1 19 AH+C +H + IVIG + I OMA 300/2 CR< 14 days 4.5
Stahl [43] 2014 CR 1 1 AH+C + E +H2 +
TA +H +





Attack frequency decrease 5–7/
month to 1.5/month
n.r.
Bayer [74] 2013 CR 1 n.r. AH +C + E +H2 +
LTRA +H + I
C1INH n.r. Improvement after 2 doses of C1INH n.r.
Perez [65] 2010 CS-1 1 2.75 AH+C + I MTX 15/1 IR = 28 days n.r.
Dosage scheme presented as milligrams administered every xweeks, unless stated otherwise. The effect of treatment is presented as initial response (IR),
complete response (CR), and partial response (PR)
CS case series,CR case report, n.r. not reported, AH antihistamine,C corticosteroids, E epinephrine,C1-inhC1 inhibitor concentrate, TA tranexamic acid,
H2 H2 antagonist, FFP fresh frozen plasma, P pantoprazole, LTRA leukotriene receptor antagonist, H hormones, AB antibiotics, I immunosuppressant,
MTX methotrexate, H hydroxychloroquine, IVIG intravenous immunoglobulin, Ica icatibant, O others
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FFP, icatibant, MTX, and omalizumab, indicating the pres-
ence of non-responders for each type of treatment in almost
each subtype of AE and also indicating that switching treat-
ment options can lead to satisfactory results in some individ-
uals even when both target a similar pathophysiological
mechanism.
We opted for a broad overview of the level of evidence of
treatment options when performing this systematic review.
This was deemed appropriate with regard to the research ques-
tion and the therapeutic problems physicians face in daily
practice. The results may be an overestimation since case re-
ports generally represent one or few patients with positive
effects of treatment, and only few cases without response are
available possibly due to underreporting. Due to the use of
different outcome measures, such as percentage of patients
with response or the time to response, it was difficult to com-
pare the results of the studies. Additionally, we found there to
be a low level of prior research evidence. Fortunately, in the
last couple of years, more extensive research has been pub-
lished, allowing for the inclusion of several RCTs in this
review. Still, our results illustrate the need for further research
in these patient groups, including prospective cohort studies
and controlled studies. The lack of available guidelines under-
lines this further. Not included in this review but worthy of
mention is the fact that it is known that AE is known to have a
detrimental effect on quality of life (QoL) [84]. While the
impact on the QoL was not a part of this review, it is striking
that this aspect was not addressed in many of the included
studies. Disease-specific questionnaires have been developed
for AE patients, both with regard to disease activity and QoL
[1, 84–86], and we consider QoL an important additional out-
come measure both in acute attacks and prophylactic setting
studies.
A minority of articles included information with respect to
adverse effects of treatment. When reported, only a few pa-
tients experienced adverse effects. These were generally mild
and self-limiting, and most were known side effects [15, 76,
87–91]. New TEAEs were oropharyngeal discomfort (report-
ed for TA), weight loss (omalizumab), and hypoesthesia,
hematuria, muscle spasms, oral candidiasis, and pain in
Table 8 Results of articles describing ineffective treatment
Author Year AE subtype Study design Size Previous therapy Ineffective therapy Dosage
Articles describing ineffective and effective treatments
Volans [31] 2013 ACEi-AE CS 2 AH+C + E TA
Schmidt [37] 2010 ACEi-AE CR 1 AH+C + E C1INH
Lipski [25] 2015 ACEi-AE CR 1 C + E FFP
Dehne [38] 2007 ACEi-AE CR 1 AH+C + E + P FFP
Colás [49] 2012 Idiop. (acute) CR 1 AH+C + E +H2 C1INH
Stahl [43] 2014 Idiop. (acute and proph.) CR 1 AH+C + E +H2 +H +AB+ LTRA TA
Icatibant
FFP
vd Elzen [62] 2014 AE with wheals CS 1 AH+ LTRA+ I MTX n.r.
Vela Vizcaino [48] 2014 Idiopathic (acute + proph.) CR 1 AH+C + E C1INH
Azofra [60] 2015 Idiop. (proph.) CS 8 AH+C, or none TA
Articles describing ONLY ineffective treatments
Illing [51] 2012 ACEi-AE CR 1 AH+C + E Icatibant 30 mg
Tran [52] 2013 Idiop. (acute) CR 1 AH+C FFP n.r.
TA
C1INHa
Maggadottir [75] 2013 AE with wheals CS-1 1 AH+ LTRA+ TCA+AB +MTX OMA
MTXb
2013 AE with wheals CS-2 1 AH+C + LTRA + IVIG + I FFP
OMA
C1INH
Idiop. idiopathic, Proph. prophylactic,CS case series,CR case report,CS-x patient number x in the specific case series, n.r. reported, AH antihistamine,C
corticosteroids, E epinephrine,C1-INHC1 inhibitor concentrate, TA tranexamic acid,H2H2 antagonist, FFP fresh frozen plasma, P pantoprazole, LTRA
leukotriene receptor antagonist,H hormones, AB antibiotics, I immunosuppressant,MTXmethotrexate, IVIG intravenous immunoglobulin, Ica icatibant,
TCA tricyclic antidepressant
a Icatibant effective, not included due to insufficient details
b IVIG effective, not included due to insufficient details
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Therapy SAEs No. of patients with >1
TEAE
TEAEs





30 (51.7 %) vs. 8 (44.4 %);
13/30 related
AE (20 cases); headache and





candidiasis, pain in extremity,
and pruritic rash (1 each).
Bernstein [7] ACEi-induced 26 + 24 Ecallantide 2 (7.7%) vs. 6 (25%),
none related
18 (75 %) vs. 17 (65.4 %);
none related
n.a.
Nanda [42] Idiopathic 1 Ecallantide 0 0 n.a.





reactions in >12 (80 %)
Bova [21] ACEi-induced 13 Icatibant n.r. 1 Injection site pain
Bas [6] ACEi-induced 8 Icatibant 0 8 Injection site erythema and/or
itching
Crooks [27] ACEi-induced 1 Icatibant 0 1 Injection site erythema
Lleonart [46] Idiopathic 1 Icatibant 0 1 Injection site pain
Mansi [19] Idiopathic 44 TA n.r. 5 Migraine, menstrual irregularities,
dyspepsia, diarrhea
Wintenberger [55] Idiopathic 25 TA 0 11 Abdominal pain, dizziness,
weakness, pain in lower
limbs, migraine
Du-Thanh [58] Idiopathic 25 TA n.r. 1 Digestive intolerance
Firinu [56] Idiopathic 16 TA n.r. Uncleara Abdominal discomfort and
migraine (1 case), abdominal
discomfort (unclear)




Rijo Calderon [54] AE with
wheals
10 OMA n.r. 7a Drowsiness (n = 7), digestive,
cutaneous symptoms, and
weight loss (5)
Azofra [60] Idiopathic 8 OMA 0 0 n.a.
Rijo Calderon [54] Idiopathic 4 OMA n.r. 7a Drowsiness (n = 7), digestive,
cutaneous symptoms, and
weight loss (5)
vd Elzen [62] AE with
wheals
3 OMA 0 2 Headache in patient co-treated
with cyclosporine, malaise
(1 case each)
Buyukozturk [64] Idiopathic 2 OMA 0 0 n.a.
Groffik [63] AE with
wheals
2 OMA 0 3/9a Headache, blood pressure
decrease, fatigue; self-limiting
3–4 days after first 3 injections
Buyukozturk [64] AE with
wheals
1 OMA 0 0 n.a.
Ghazanfar [66] AE with
wheals
1 OMA 0 0 n.a.
Sanchez-Machin [70] AE with
wheals
1 OMA 0 0 n.a.
von Websky [72] Idiopathic 1 OMA 0 0 n.a.
Suna [73] Idiopathic 1 OMA 0 0 n.a.
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extremity (ecallantide; TEAEs may be unrelated). Notably, for
icatibant, only injection-related TEAEs occurred.
In conclusion, for patients suffering angioedema refrac-
tory to conservative treatment, several additional treatment
options are available with rapid time to response, high re-
sponse rates, and limited side effects. However, these ther-
apies are off-label, and there is a need for additional studies
to provide a high level of scientific evidence. Treatment
options differ per subtype of AE. Most promising treat-
ments for acute attacks (ACEi-AE and idiopathic AE) con-
sist of icatibant, C1INH, and FFP, with response often
within 2 h and with limited side effects. For prophylactic
treatment (idiopathic AE and AE with wheals), the most
promising options are omalizumab, TA, and C1INH, with
efficacy in a majority of patients, together with limited side
effects.
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